| Bristol-Myers Squibb Company (BMY) | |||
|---|---|---|---|
| 50.45 5.18 (11.44%) | 07-26 16:00 | ||
| Open: | 48.27 | Pre. Close: | 45.27 |
| High: | 50.61 | Low: | 47.73 |
| Volume: | 31,408,167 | Market Cap: | 102,267(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 59.11  One year: 69.04 |
| Support: | Support1: 43.65 Support2: 39.35 |
| Resistance: | Resistance1: 50.61 Resistance2: 59.11 |
| Pivot: | 42.58 |
| Moving Averages: | MA(5): 45.21 MA(20): 42.09 MA(100): 45.69  MA(250): 50.79 |
| MACD: | MACD(12,26): 1.16 Signal(12,26,9): 0.29 |
| %K %D: | %K(14,3): 95.26 %D(3): 87.46 |
| RSI: | RSI(14): 81.87 |
| 52-Week: | High: 63.41 Low: 39.35 Change(%): -17.8 |
| Average Vol(K): | 3-Month: 15527 10-Days: 17224 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 50.64 - 50.79 | 50.79 - 50.958 |
| Low: | 47.289 - 47.466 | 47.466 - 47.665 |
| Close: | 50.124 - 50.403 | 50.403 - 50.716 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BMY ] has closed above the upper band by 25.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 118.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
| Company profile |
|---|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: New York Stock Exchange | |
| Sector: Healthcare | |
| Industry: Drug Manufacturers - General | |
| Shares Out. (M) | 2030.00 |
| Shares Float (M) | 2020.00 |
| % Held by Insiders | 0.10 |
| % Held by Institutions | 79.11 |
| Shares Short (K) | 31620 |
| Shares Short Prior Month (K) | 28730 |
| Stock Financials | |
|---|---|
| EPS | -3.100 |
| Book Value (p.s.) | 8.140 |
| Profit Margin | -13.50 |
| Operating Margin | 19.25 |
| Return on Assets (ttm) | 5.4 |
| Return on Equity (ttm) | -25.3 |
| Qtrly Rev. Growth | 4.7 |
| Gross Profit (p.s.) | |
| Sales Per Share | 22.429 |
| EBITDA (p.s.) | 8.951 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | 13720.00 |
| Levered Free Cash Flow (M) | 16370.00 |
| Stock Valuation | |
|---|---|
| PE Ratio | -16.27 |
| PEG Ratio | -17.27 |
| Price to Book value | 6.20 |
| Price to Sales | 2.25 |
| Price to Cash Flow | 7.46 |
| Stock Dividends | |
|---|---|
| Dividend | 0.600 |
| Dividend Yield | 0.01 |
| Dividend Growth | |
